Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.39 |
| ▸ | STS | P08842 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 3/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | BMP1 | P13497 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19613246 | 0.94 | GPR119 (0.41) | GPR119STSEPHX2SCN1ASCN8A | |
| SCHEMBL19627661 | 0.94 | SCN1A (0.41) | GPR119STSEPHX2SCN1ASCN8A | |
| SCHEMBL19631616 | 0.91 | PIK3CD (0.38) | GPR119STSEPHX2SCN1ASCN8A | |
| SCHEMBL19614227 | 0.89 | SCN1A (0.43) | GPR119STSEPHX2SCN1ASCN8A | |
| SCHEMBL19627667 | 0.86 | SCN8A (0.37) | GPR119STSEPHX2SCN1ASCN8A | |
| SCHEMBL19627603 | 0.86 | SCN8A (0.46) | GPR119STSSCN1ASCN8APDE4A | |
| SCHEMBL19631534 | 0.85 | SCN8A (0.41) | GPR119STSEPHX2SCN1ASCN8A | |
| SCHEMBL22590192 | 0.85 | GPR119 (0.44) | GPR119STSEPHX2SCN1ASCN8A | |
| SCHEMBL21117647 | 0.83 | MAPT (0.33) | GPR119STSEPHX2SLC2A1BMP1 | |
| SCHEMBL19631702 | 0.81 | SCN1A (0.37) | GPR119STSEPHX2SCN1ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | GPR119 1866/4885STS 181/4885EPHX2 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.